To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after treatment with SGLT2 inhibitors
Diagnosed T2DM on antidiabetic medication not including SGLT2 inhibitors.
HbA1c ≤ 7%.
Age 40-75 years.
Sinus rhythm.
History of atrial fibrillation or flutter.
Patients treated with SGLT2 inhibitors.
Severe mitral valve regurgitation or stenosis.
Previous myocardial infarction.
Adults aged 40-75 years with a diagnosis of T2DM on stable antidiabetic therapy not including SGLT2 inhibitors
Cohort
Prospective
Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Drugevaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors
follow-up and evaluation of LA remodeling in patients with type-2 diabetes mellitus ( T2DM) before and after treatment with SGLT2 inhibitors
The study aims evaluation and follow-up of Left Atrial Strain Parameters assessed by Speckle-Tracking Echocardiography (STE) before and after treatment with SGLT2 inhibitors in patients with type-2 diabetes mellitus at Baseline and 6 months follow-up . Left atrial strain will be measured using 2D speckle-tracking echocardiography, including reservoir strain (%), conduit strain (%), and contraction strain (%)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
